Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores, and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids.

The Granulomatosis with Polyangiitis drugs in development market research report provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Granulomatosis with Polyangiitis and features dormant and discontinued projects.

Key Targets in the Granulomatosis with Polyangiitis Pipeline Products Market

The key targets in the Granulomatosis with Polyangiitis pipeline products market are Cells Expressing B Lymphocyte Antigen CD20, Interleukin 5, Complement C5, Interleukin 2 Receptor, Interleukin 5 Receptor Subunit Alpha, Interleukin 6 Receptor, T Lymphocyte Activation Antigen CD80, T Lymphocyte Activation Antigen CD86, and Tyrosine Protein Kinase JAK1.

Granulomatosis with Polyangiitis Pipeline Products Analysis Market by Targets

Granulomatosis with Polyangiitis Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Granulomatosis with Polyangiitis Pipeline Products Market

The key mechanisms of action in the Granulomatosis with Polyangiitis pipeline products market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Interleukin 5 Inhibitor, Complement C5 Inhibitor, Interleukin 2 Receptor Agonist, Interleukin 5 Receptor Subunit Alpha Antagonist, Interleukin 6 Receptor Antagonist, T Lymphocyte Activation Antigen CD80 Inhibitor, T Lymphocyte Activation Antigen CD86 Inhibitor, and Tyrosine Protein Kinase JAK1 Inhibitor.

Granulomatosis with Polyangiitis Pipeline Products Market Analysis by Mechanism of Actions

Granulomatosis with Polyangiitis Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

Key Routes of Administration in the Granulomatosis with Polyangiitis Pipeline Products Market

The key routes of administration in the Granulomatosis with Polyangiitis pipeline products market are intravenous, subcutaneous, oral, and parenteral.

Granulomatosis with Polyangiitis Pipeline Products Market Analysis by Routes of Administration

Granulomatosis with Polyangiitis Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Granulomatosis with Polyangiitis Pipeline Products Market

The key molecule types in the Granulomatosis with Polyangiitis pipeline products market are monoclonal antibody, fusion protein, and recombinant protein.

Granulomatosis with Polyangiitis Pipeline Products Market Analysis by Molecule Type

Granulomatosis with Polyangiitis Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Major Companies in the Granulomatosis with Polyangiitis Pipeline Products Market

Some of the major companies in the Granulomatosis with Polyangiitis pipeline products market are GlaxoSmithKline Plc, Biogen Inc, Bristol-Myers Squibb Co, Chugai Pharmaceutical Co Ltd, iBio Inc, Iltoo Pharma, InflaRx NV, Kyowa Kirin Co Ltd, Mabion SA, and Nanolek.

Granulomatosis with Polyangiitis Pipeline Products Market Analysis by Companies

Granulomatosis with Polyangiitis Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key targets Cells Expressing B Lymphocyte Antigen CD20, Interleukin 5, Complement C5, Interleukin 2 Receptor, Interleukin 5 Receptor Subunit Alpha, Interleukin 6 Receptor, T Lymphocyte Activation Antigen CD80, T Lymphocyte Activation Antigen CD86, and Tyrosine Protein Kinase JAK1
Key mechanism of action Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Interleukin 5 Inhibitor, Complement C5 Inhibitor, Interleukin 2 Receptor Agonist, Interleukin 5 Receptor Subunit Alpha Antagonist, Interleukin 6 Receptor Antagonist, T Lymphocyte Activation Antigen CD80 Inhibitor, T Lymphocyte Activation Antigen CD86 Inhibitor, and Tyrosine Protein Kinase JAK1 Inhibitor
Key routes of administration Intravenous, Subcutaneous, Oral, and Parenteral
Key molecule type Monoclonal Antibody, Fusion Protein, and Recombinant Protein
Major companies GlaxoSmithKline Plc, Biogen Inc, Bristol-Myers Squibb Co, Chugai Pharmaceutical Co Ltd, iBio Inc, Iltoo Pharma, InflaRx NV, Kyowa Kirin Co Ltd, Mabion SA, and Nanolek

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Granulomatosis with Polyangiitis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Granulomatosis with Polyangiitis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Granulomatosis with Polyangiitis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Granulomatosis with Polyangiitis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Granulomatosis with Polyangiitis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Overview

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Companies Involved in Therapeutics Development

Biogen Inc

Bristol-Myers Squibb Co

Chugai Pharmaceutical Co Ltd

GlaxoSmithKline Plc

iBio Inc

Iltoo Pharma

InflaRx NV

Kyowa Kirin Co Ltd

Mabion SA

Nanolek

Nichi-Iko Pharmaceutical Co Ltd

Nippon Shinyaku Co Ltd

Pharmapraxis

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Drug Profiles

abatacept – Drug Profile

Product Description

Mechanism Of Action

History of Events

aldesleukin – Drug Profile

Product Description

Mechanism Of Action

History of Events

benralizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

depemokimab – Drug Profile

Product Description

Mechanism Of Action

mepolizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

NS-229 – Drug Profile

Product Description

Mechanism Of Action

rituximab – Drug Profile

Product Description

Mechanism Of Action

History of Events

rituximab biobetter – Drug Profile

Product Description

Mechanism Of Action

rituximab biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

rituximab biosimilar – Drug Profile

Product Description

Mechanism Of Action

rituximab biosimilar – Drug Profile

Product Description

Mechanism Of Action

rituximab biosimilar – Drug Profile

Product Description

Mechanism Of Action

tocilizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

vilobelimab – Drug Profile

Product Description

Mechanism Of Action

History of Events

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Dormant Projects

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Discontinued Products

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Product Development Milestones

Featured News & Press Releases

Oct 29, 2020: GSK Nucala (mepolizumab) filings accepted by European Medicines Agency for three additional eosinophil-driven diseases

Jan 30, 2020: The CHMP recommended extensions of indication for MabThera

Oct 09, 2019: Two new options for self-administration of NUCALA now approved in Canada, making it the first anti-IL5 biologic to offer patients with severe eosinophilic asthma a choice of how and where to receive treatment

Sep 30, 2019: Roche’s Rituxan secures approval for first paediatric indication

Jun 12, 2019: FDA grants priority review to Genentech’s Rituxan (Rituximab) in children with two rare blood vessel disorders

May 16, 2019: GSK presents Nucala at ATS 2019

Nov 27, 2018: FDA grants ODD for AstraZeneca’s Fasenra to treat EGPA

Nov 15, 2018: Roche receives positive CHMP opinion to expand MabThera for the treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Dec 12, 2017: GSK Achieves Approval for Nucala (mepolizumab) for the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) for Adults in the US

Jun 28, 2017: GSK announces US regulatory submission for mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Mar 25, 2014: NICE says yes to new treatment for rare autoimmune disease in final guidance

Feb 14, 2014: GSK announces start of Phase lll study for mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis

Mar 22, 2013: Roche Receives CHMP Positive Opinion For MabThera

Apr 19, 2011: Genentech Receives FDA Approval For Rituxan Plus Steroid For Use In Severe Forms Of Vasculitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis), 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Pipeline by Biogen Inc, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Pipeline by Bristol-Myers Squibb Co, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Pipeline by Chugai Pharmaceutical Co Ltd, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Pipeline by GlaxoSmithKline Plc, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Pipeline by iBio Inc, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Pipeline by Iltoo Pharma, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Pipeline by InflaRx NV, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Pipeline by Kyowa Kirin Co Ltd, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Pipeline by Mabion SA, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Pipeline by Nanolek, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Pipeline by Nichi-Iko Pharmaceutical Co Ltd, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Pipeline by Nippon Shinyaku Co Ltd, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Pipeline by Pharmapraxis, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Dormant Projects, 2022

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.